Section Arrow
REPL.NASDAQ
- Replimune Group
Quotes are at least 15-min delayed:2024/12/23 22:23 EST
Last
 12.34
-0.15 (-1.20%)
Day High 
12.97 
Prev. Close
12.49 
1-M High
17 
Volume 
709.19K 
Bid
11.38
Ask
13.3
Day Low
12.175 
Open
12.97 
1-M Low
11 
Market Cap 
961.18M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 12.33 
20-SMA 13 
50-SMA 12.2 
52-W High 17 
52-W Low 4.92 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.04/-2.93
Enterprise Value
1.03B
Balance Sheet
Book Value Per Share
4.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:23 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.